The company has expanded its laboratory test portfolio with five new molecular, serology, and functional assays for COVID-19 vaccine and therapy development programs.
PPD announced on June 25, 2020 that it has expanded its laboratory test portfolio with five new molecular, serology, and functional assays for COVID-19 vaccine and therapy development programs.
According to a company press release, the molecular assays will use reverse transcriptase, polymerase chain reaction (RT–PCR), a system that helps diagnose diseases and give a measure of gene expression, to aid in detecting SARS-CoV-2 and pinpoint the number of infectious particles to determine viral load. The assays work to target spike proteins that are specific to SARS-CoV-2 and nucleocapsid proteins that are more common in the coronavirus family.
PPD has developed two enzyme-linked immunosorbent assays for vaccine trials to identify immunoglobulin G to full-length recombinant protein for spike and for nucleocapsid, the press release said. The company has also created a plate-based functional assay to find anti-spike antibodies in human serum that can avoid infection by disrupting the binding of angiotensin converting enzyme 2 (ACE2) to SARS-CoV-2 spike protein.
“PPD Laboratories is fully committed to helping our customers bring COVID-19 vaccines and therapies to fruition,” said Christopher Fikry, MD, executive vice-president of PPD Laboratories, in the press release. “The addition of these five assays to our test portfolio will enable us to expand our support of many important COVID-19 trials. We’ve also incorporated innovative measures so trials can start more quickly, run more efficiently, and conclude sooner.”
Source: PPD
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 5th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.